<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966235</url>
  </required_header>
  <id_info>
    <org_study_id>MelonCAC</org_study_id>
    <nct_id>NCT03966235</nct_id>
  </id_info>
  <brief_title>Melatonin on Coronary Artery Calcification</brief_title>
  <acronym>MelonCAC</acronym>
  <official_title>Effects of Melatonin on Progression of Coronary Artery Calcification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We planned to evaluate the effects of melatonin on progression of coronary artery
      calcification (CAC) in patients with moderate calcified coronary atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CAC is prevalent in coronary artery disease (CHD), and the extent of CAC predicts
      cardiovascular risk. The causes of CAC include dysregulated matrix metabolism, epitaxial
      mineral deposition, inflammation, oxidative stress, and apoptosis. Melatonin is the main
      indoleamine produced by the pineal gland; it is known recently to have anti-inflammatory,
      anti-cancer and antioxidant activities. Several studies have shown that melatonin protects
      against inflammation and apoptosis in vascular calcification. Melatonin also inhibits
      oxidative stress-induced apoptosis and calcification in endplate chondrocytes. The
      investigators planned to determine the efficacy of melatonin on progression of coronary
      artery calcification (CAC) in patients with moderate calcified coronary atherosclerosis. This
      study may shed light as to whether oral melatonin supplementation can be an adjunct therapy
      in CAC patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a change in CAC score at 6 months measured by coronary CTA</measure>
    <time_frame>at 6 months</time_frame>
    <description>The primary efficacy endpoint was the effect of melatonin on the change in CAC score at 6 months compared with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>high-sensitivity C-reactive protein (hsCRP) level</measure>
    <time_frame>at 6 months</time_frame>
    <description>a change in high-sensitivity C-reactive protein (hsCRP) level at 6 months after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malondialdehyde (MDA) level</measure>
    <time_frame>at 6 months</time_frame>
    <description>a change in malondialdehyde (MDA) level at 6 months after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Coronary Artery Calcification</condition>
  <arm_group>
    <arm_group_label>Melatonin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug: melatonin tablets (Sigma‐Aldrich Co. LLC, St. Louis, MO, USA); the frequency:3mg melatonin tablet was taken daily; duration: study treatment was maintained for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug: placebo tablet; the frequency: placebo tablet was taken daily; duration: study treatment was maintained for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 3 mg</intervention_name>
    <description>Melatonin was taken daily for 6 months.</description>
    <arm_group_label>Melatonin group</arm_group_label>
    <other_name>melatonin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet was taken daily for 6 months.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with a documented Agatston score≥30 and moderate calcified coronary
        atherosclerosis (&lt;50% diameter lumen narrowing) were eligible for the study.

        Exclusion Criteria:

          1. unstable angina pectoris

          2. symptomatic chronic heart failure and/or left ventricular ejection fraction (EF) &lt;40%

          3. atrial fibrillation or other arrhythmias

          4. type I diabetes mellitus or uncontrolled type II diabetes mellitus

          5. renal failure

          6. liver disease

          7. gastrointestinal disease that affected absorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yu jie zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wei ren chen, MD</last_name>
    <phone>+8601066876231</phone>
    <email>chen_weiren@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wei ren chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gilham D, Tsujikawa LM, Sarsons CD, Halliday C, Wasiak S, Stotz SC, Jahagirdar R, Sweeney M, Johansson JO, Wong NCW, Kalantar-Zadeh K, Kulikowski E. Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis. 2019 Jan;280:75-84. doi: 10.1016/j.atherosclerosis.2018.11.002. Epub 2018 Nov 14.</citation>
    <PMID>30476723</PMID>
  </reference>
  <reference>
    <citation>Shobeiri N, Bendeck MP. Interleukin-1β Is a Key Biomarker and Mediator of Inflammatory Vascular Calcification. Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):179-180. doi: 10.1161/ATVBAHA.116.308724.</citation>
    <PMID>28122774</PMID>
  </reference>
  <reference>
    <citation>Fernández A, Ordóñez R, Reiter RJ, González-Gallego J, Mauriz JL. Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis. J Pineal Res. 2015 Oct;59(3):292-307. doi: 10.1111/jpi.12264. Epub 2015 Aug 9. Review.</citation>
    <PMID>26201382</PMID>
  </reference>
  <reference>
    <citation>Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, Ghaznavi H, Naseripour M. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018 Jan 15;193:20-33. doi: 10.1016/j.lfs.2017.12.001. Epub 2017 Dec 5. Review.</citation>
    <PMID>29203148</PMID>
  </reference>
  <results_reference>
    <citation>Wang Z, Ni L, Wang J, Lu C, Ren M, Han W, Liu C. The protective effect of melatonin on smoke-induced vascular injury in rats and humans: a randomized controlled trial. J Pineal Res. 2016 Mar;60(2):217-27. doi: 10.1111/jpi.12305. Epub 2016 Jan 13.</citation>
    <PMID>26681403</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chen Wei Ren, MD</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>coronary artery calcification</keyword>
  <keyword>adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

